Differential associations of statin and fibrate treatment with carotid arterial remodeling

Am J Hypertens. 2005 Nov;18(11):1476-81. doi: 10.1016/j.amjhyper.2005.05.019.

Abstract

Background: The effects of statins on intima-media thickness (IMT) are well documented, whereas those of fibrates are unknown. Therefore we compared IMT under treatment with each class of drugs.

Methods: We studied a cohort of consecutive dyslipidemic subjects treated with statin (n = 291) or fibrate (n = 82) drugs. Fibrate-treated subjects were matched with the same number of statin-treated subjects to obtain two subgroups of similar demographic and risk factors including LDL cholesterol. Common carotid far wall IMT and lumen diameter were measured by ultrasonography.

Results: In the entire study population, IMT was greater in the fibrate group than in the statin group (P < .001), even after adjustment for LDL cholesterol and other covariates (P < .05). In the matched groups, IMT was greater in fibrate group than in the statin group (P < .01), even after adjustment for LDL cholesterol and other covariates including treatment duration (P < .01). The IMT correlated positively with treatment duration in the fibrate group (P < 0.05) but not in the statin group. In addition, IMT correlated positively with carotid lumen diameter in both the fibrate and statin groups (P < .05, P < .01) but with a lower slope in the former (P < .05).

Conclusions: In this study fibrate treatment was associated with greater IMT, steeper IMT-time relationship, and lower compensatory carotid enlargement than was statin treatment. These differences were not explained by differences in LDL cholesterol.

Publication types

  • Comparative Study

MeSH terms

  • Adult
  • Atorvastatin
  • Bezafibrate / therapeutic use
  • Body Mass Index
  • Carotid Arteries / drug effects*
  • Carotid Arteries / pathology
  • Carotid Arteries / physiopathology
  • Cholesterol, HDL / blood
  • Clofibric Acid / analogs & derivatives
  • Clofibric Acid / therapeutic use*
  • Cohort Studies
  • Dyslipidemias / blood
  • Dyslipidemias / drug therapy*
  • Dyslipidemias / physiopathology
  • Fatty Acids, Monounsaturated / therapeutic use
  • Female
  • Fenofibrate / therapeutic use
  • Fibric Acids
  • Fluvastatin
  • Gemfibrozil / therapeutic use
  • Heptanoic Acids / therapeutic use
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use*
  • Hypolipidemic Agents / therapeutic use*
  • Indoles / therapeutic use
  • Male
  • Middle Aged
  • Multivariate Analysis
  • Pravastatin / therapeutic use
  • Pyridines / therapeutic use
  • Pyrroles / therapeutic use
  • Risk Factors
  • Simvastatin / therapeutic use
  • Treatment Outcome
  • Tunica Intima / diagnostic imaging
  • Tunica Media / diagnostic imaging
  • Ultrasonography

Substances

  • Cholesterol, HDL
  • Fatty Acids, Monounsaturated
  • Fibric Acids
  • Heptanoic Acids
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Hypolipidemic Agents
  • Indoles
  • Pyridines
  • Pyrroles
  • Fluvastatin
  • Clofibric Acid
  • Atorvastatin
  • Simvastatin
  • cerivastatin
  • ciprofibrate
  • Pravastatin
  • Gemfibrozil
  • Fenofibrate
  • Bezafibrate